Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Niagen Bioscience IncNASDAQ: NAGE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $291K fell 20.9% year over year, behind the +16.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 66.3% from the prior quarter. Over 3 fiscal years it compounded at -8.4% a year.
Context
- Depreciation & amortization amounted to 1.1% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.9% toward the trailing-twelve-month pace of +16.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.45M USD
- Year-over-year change
- -2.3%
- 4-year CAGR
- -2.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.45M | -2.3% |
| FY2024 | 2024-12-31 | 1.48M | -13.0% |
| FY2023 | 2023-12-31 | 1.71M | -9.5% |
| FY2022 | 2022-12-31 | 1.88M | +15.9% |
| FY2021 | 2021-12-31 | 1.63M | — |
Depreciation & Amortization vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's LTM Mar 2026 depreciation & amortization of $1.71M is the 4th largest of the 10 companies compared; the peer median is $1.28M.
- Its year-over-year change of +16.6% is the 4th highest of 9, against a peer median of +5.0%.
- Depreciation & amortization amounts to 1.3% of revenue for NAGE, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $1.71M | +16.6% | -8.4% | 1.3% |
| LTM Mar 2026 | $1.57M | +21.0% | +30.8% | 4.7% | |
| LTM Mar 2026 | $1.28M | -96.1% | -67.7% | 0.6% | |
| LTM Dec 2025 | $1.19M | — | — | 1.0% | |
| LTM Mar 2026 | $856K | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $481K | +11.1% | -33.4% | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding NAGE) | $1.28M | +5.0% | +6.5% | 1.5% | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.13M) | (16.54M) | (4.94M) | 8.55M | 17.38M |
| Depreciation & Amortization | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.2M | 5.74M | 4.75M | 3.66M | 6.07M |
| Change in Working Capital | (4.73M) | (6.01M) | 4.62M | 3.13M | (8.3M) |
| Accounts Receivables | (2.58M) | (3.32M) | 2.26M | (1.28M) | (756K) |
| Inventory | (1.92M) | (1.08M) | 152K | 5.33M | (11.64M) |
| Accounts Payables | 978K | (744K) | 553K | (1.07M) | 2.27M |
| Other Working Capital | (1.21M) | (875K) | 1.66M | 147K | 1.83M |
| Other Non-Cash Items | (124K) | (167K) | 977K | (4.72M) | (3.17M) |
| Operating Cash Flow | (24.16M) | (15.1M) | 7.12M | 12.11M | 13.44M |
| Capital Expenditures | (409K) | (334K) | (148K) | (163K) | (292K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 5K | 20K | 0 |
| Investing Cash Flow | (409K) | (334K) | (143K) | (143K) | (292K) |
| Debt Repayment | (31K) | (16K) | (15K) | (11K) | (12K) |
| Common Stock Issued | 26.74M | 7.75M | 0 | 5.43M | 7.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (251K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.39M | (77K) | (75K) | (52K) | 0 |
| Financing Cash Flow | 36.09M | 7.65M | (90K) | 5.37M | 6.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.52M | (7.78M) | 6.88M | 17.34M | 20.13M |
| Free Cash Flow | (24.57M) | (15.43M) | 6.97M | 11.95M | 13.15M |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.